1. Renaud J-P, Chung C, Danielson H, Egner U, Hennig M, et al. 2016. Biophysics in drug discovery : impact, challenges and opportunities. Nat. Rev. Drug Discov. 15:679–98
2. Raynal B, Lenormand P, Baron B, Hoos S, England P. 2014. Quality assessment and optimization of purified protein samples : why and how ? Microb. Cell Fact. 13(180):1–10
3. Hardy D, Desuzinges E, Rothnie AJ, Jawhari A. 2018. The yin and yang of solubilization and stabilization for wild-type and full-length membrane protein. Methods. 147:118–25
4. Corradi V, Sejdiu BI, Mesa-galloso H, Abdizadeh H, Noskov SY, et al. 2019. Emerging Diversity in Lipid − Protein Interactions. Chem. Rev. 119:5775–5848
5. Hulme EC, Trevethick MA. 2010. Ligand binding assays at equilibrium : validation. Br. J. Pharmacol. 161:1219–37
6. Flanagan CA. GPCR-radioligand binding assays, Vol. 132. Elsevier Ltd. 191–215 pp.
7. Stoddart LA, White CW, Nguyen K, Hill SJ, Pfleger KDG. 2016. approaches to study GPCR ligand binding Tables of Links. Br. J. Pharmacol. 173:3028–37
8. Veiksina S, Kopanchuk S, Rinken A. 2010. Fluorescence anisotropy assay for pharmacological characterization of ligand binding dynamics to melanocortin 4 receptors. Anal. Biochem. 402(1):32–39
9. Rinken A, Lavogina D, Kopanchuk S. 2018. Assays with Detection of Fluorescence Anisotropy: Challenges and Possibilities for Characterizing Ligand Binding to GPCRs. Trends Pharmacol. Sci. 39(2):187–99
10. Bartoschik T, Gupta A, Kern B, Hitchcock A, Adams NBP, Tschammer N. 2021. Quantifying the Interaction of Phosphite with ABC Transporters: MicroScale Thermophoresis and a Novel His-Tag Labeling Approach. In Methods in molecular biology, pp. 51–62
11. Corin K, Baaske P, Geissler S, Wienken CJ, Duhr S, et al. 2011. Structure and function analyses of the purified GPCR human vomeronasal type 1 receptor 1. Sci. Rep. 1:1–6
12. Wienken CJ, Baaske P, Rothbauer U, Braun D, Duhr S. 2010. Protein-binding assays in biological liquids using microscale thermophoresis. Nat. Commun. 1(7):
13. Liberelle M, Magnez R, Thuru X, Bencheikh Y, Ravez S, et al. 2019. MUC4-ErbB2 Oncogenic Complex: Binding studies using Microscale Thermophoresis. Sci. Rep. 9(1):1–8
14. Seidel SAI, Dijkman PM, Lea WA, van den Bogaart G, Jerabek-Willemsen M, et al. 2013. Microscale thermophoresis quantifies biomolecular interactions under previously challenging conditions. Methods. 59(3):301–15
15. Torres OB, Duval AJ, Sulima A, Antoline JFG, Jacobson AE, et al. 2018. A rapid solution-based method for determining the affinity of heroin hapten-induced antibodies to heroin, its metabolites, and other opioids. Anal. Bioanal. Chem. 410(16):3885–3903
16. Dijkman PM, Watts A. 2015. Lipid modulation of early G protein-coupled receptor signalling events. Biochim. Biophys. Acta - Biomembr. 1848(11):2889–97
17. Yoshida K, Nagatoishi S, Kuroda D, Suzuki N, Murata T, Tsumoto K. 2019. Phospholipid Membrane Fluidity Alters Ligand Binding Activity of a G Protein-Coupled Receptor by Shifting the Conformational Equilibrium. Biochemistry. 58(6):504–8
18. Bada Juarez JF, Muñoz-García JC, Inácio dos Reis R, Henry A, McMillan D, et al. 2020. Detergent-free extraction of a functional low-expressing GPCR from a human cell line. Biochim. Biophys. Acta - Biomembr. 1862(3):183152
19. Im D, Inoue A, Fujiwara T, Nakane T, Yamanaka Y, et al. 2020. with the antipsychotic drug spiperone. Nat. Commun., pp. 1–11
20. Alves I, Staneva G, Tessier C, Salgado GF, Nuss P. 2011. The interaction of antipsychotic drugs with lipids and subsequent lipid reorganization investigated using biophysical methods. Biochim. Biophys. Acta. 1808:2009–18
21. Sykes DA, Moore H, Stott L, Holliday N, Javitch JA, et al. 2017. Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors. Nat. Commun. 8(1):1–11
22. Jarmoskaite I, Alsadhan I, Vaidyanathan PP, Chem-h S, States U. 2020. How to measure and evaluate binding affinities. Elife. 9(e57264):
23. TAG-LITE ® DOPAMINE D2 RECEPTOR. 2015. www.cisbio.com
24. Lane JR, Abramyan AM, Adhikari P, Keen AC, Lee K, et al. 2020. Distinct inactive conformations of the dopamine D2 and D3 receptors correspond to different extents of inverse agonism. Elife. 9(e52189):1–26